Allergan plc (NYSE:AGN)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $181.62 and last traded at $181.52, with a volume of 1176706 shares traded. The stock had previously closed at $181.28.
A number of equities research analysts have recently issued reports on the company. Svb Leerink reaffirmed a “market perform” rating and set a $188.00 target price (down from $217.00) on shares of Allergan in a research report on Thursday, July 18th. Barclays boosted their target price on Allergan from $176.00 to $188.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 7th. UBS Group boosted their target price on Allergan from $172.00 to $189.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. ValuEngine lowered Allergan from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th. Finally, Sanford C. Bernstein lowered Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price target on the stock. in a research report on Tuesday, July 16th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $175.16.
The stock has a market capitalization of $59.48 billion, a price-to-earnings ratio of 10.88, a price-to-earnings-growth ratio of 2.11 and a beta of 1.66. The company has a quick ratio of 0.91, a current ratio of 1.67 and a debt-to-equity ratio of 0.39. The firm has a 50-day moving average of $172.20 and a two-hundred day moving average of $156.12.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $4.25 earnings per share for the quarter, meeting the consensus estimate of $4.25. The firm had revenue of $4.03 billion for the quarter, compared to analyst estimates of $3.88 billion. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. Allergan’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $4.25 earnings per share. As a group, sell-side analysts predict that Allergan plc will post 16.7 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Wednesday, November 13th will be given a dividend of $0.74 per share. This represents a $2.96 annualized dividend and a yield of 1.63%. The ex-dividend date is Tuesday, November 12th. Allergan’s payout ratio is 17.74%.
A number of hedge funds and other institutional investors have recently modified their holdings of AGN. Cacti Asset Management LLC grew its stake in Allergan by 0.9% in the second quarter. Cacti Asset Management LLC now owns 215,018 shares of the company’s stock valued at $35,908,000 after purchasing an additional 2,009 shares in the last quarter. Boltwood Capital Management grew its stake in Allergan by 25.9% in the second quarter. Boltwood Capital Management now owns 4,985 shares of the company’s stock valued at $835,000 after purchasing an additional 1,025 shares in the last quarter. Fulton Bank N.A. grew its stake in Allergan by 19.9% in the second quarter. Fulton Bank N.A. now owns 14,220 shares of the company’s stock valued at $2,381,000 after purchasing an additional 2,360 shares in the last quarter. Woodstock Corp grew its stake in Allergan by 1.4% in the second quarter. Woodstock Corp now owns 14,532 shares of the company’s stock valued at $2,433,000 after purchasing an additional 200 shares in the last quarter. Finally, Metropolis Capital Ltd grew its stake in Allergan by 41.5% in the second quarter. Metropolis Capital Ltd now owns 321,088 shares of the company’s stock valued at $53,760,000 after purchasing an additional 94,220 shares in the last quarter. Hedge funds and other institutional investors own 80.70% of the company’s stock.
About Allergan (NYSE:AGN)
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
See Also: What is Blockchain?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.